The notices it replaced
- Reissues: PAR-24-085 National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- 2 steps back: PAR-21-033 National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- 3 steps back: PAR-18-560 National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trials Required)
Who won it before
216 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $129,412,466 in first-year total cost, median $623,000.
Most frequent study sections
- Clinical Oncology Study Section[CONC]106
- Imaging Guided Interventions and Surgery Study Section[IGIS]17
- Radiation Therapeutics and Biology Study Section[RTB]14
- Developmental Therapeutics Study Section[DT]10
- Imaging Probes and Contrast Agents Study Section[IPCA]9
Most frequent institutions
- SLOAN-KETTERING INST CAN RESEARCH17
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE16
- UNIVERSITY OF TX MD ANDERSON CAN CTR16
- OHIO STATE UNIVERSITY12
- WASHINGTON UNIVERSITY12
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Fluorescence guided nerve sparing during colorectal cancer surgery using local application of a near infrared nerve fluorophore1R01CA303975-01 · under PAR-24-085 | ALANI, ADAM G.GIBBS, SUMMER LYNNE | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $2,491,138 | IGIS |
| 2025 | Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinic1R01CA303579-01 · under PAR-24-085 | BASAR, RAFETDAHER, MAYREZVANI, KATY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $1,847,485 | CIC |
| 2025 | A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers2R01CA238392-06 · under PAR-24-085 | LEE, NANCY Y | SLOAN-KETTERING INST CAN RESEARCH, NY | $777,228 | ZRG1 |
| 2025 | CMV-specific CD19 CAR T cells amplified in vivo using CMV Triplex vaccine for B-NHL1R01CA296280-01 · under PAR-24-085 | NAKAMURA, RYOTAROWANG, XIULI | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $738,698 | CONC |
| 2025 | Anti-CD38 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Myelogenous Leukemia1R01CA292596-01A1 · under PAR-24-085 | SHIVELY, JOHN ERNESTWONG, JEFFREY Y | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $738,698 | RTB |
| 2025 | Improving CDK4/6 inhibition therapy for patients with liposarcoma by understanding resistance1R01CA296835-01A1 · under PAR-24-085 | ANTONESCU, CRISTINA RTAP, WILLIAM D. | SLOAN-KETTERING INST CAN RESEARCH, NY | $727,732 | ATA |
| 2025 | DLL3-targeted IL18-secreting CAR T cells in Small Cell Lung Cancer1R01CA303470-01 · under PAR-24-085 | SCHOENFELD, ADAM J | SLOAN-KETTERING INST CAN RESEARCH, NY | $716,521 | CONC |
| 2025 | Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.1R01CA293348-01A1 · under PAR-24-085 | SADEGHI, SARMAD | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | $712,735 | CONC |
| 2025 | Placebo-Controlled Phase II Randomized Clinical Trial of Photobiomodulation Therapy in Head and Neck Cancer Survivors with Chronic Lymphedema1R01CA289307-01A1 · under PAR-24-085 | DENG, JIELIN, ALEXANDERMURPHY, BARBARA A. | UNIVERSITY OF PENNSYLVANIA, PA | $706,669 | CONC |
| 2025 | Early phase clinical trials of 211At-meta-astatobenzylguanidine for children with neuroblastoma and adults with advanced neuroendocrine cancers1R01CA300202-01 · under PAR-24-085 | NARAYAN, VIVEK | UNIVERSITY OF PENNSYLVANIA, PA | $695,205 | RTB |
| 2025 | Pharmacodynamically directed targeted therapy for leukemia1R01CA292084-01A1 · under PAR-24-085 | BYRD, JOHN C.COSS, CHRISTOPHER C.HERTLEIN, ERIN KMIMS, ALICE SCOTT | UNIVERSITY OF CINCINNATI, OH | $683,472 | ATA |
| 2025 | Prognostic and Therapeutic Roles of Voltage Gated Potassium Channels in Managing KIT Mutant Gastrointestinal Stromal Tumors (GIST)1R01CA292590-01A1 · under PAR-24-085 | SICKLICK, JASON KEITH | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $662,682 | CONC |
| 2025 | Tumor-Selective Radiosensitization by Targeting Hypoxia in Rectal Cancer1R01CA297752-01 · under PAR-24-085 | WILLIAMS, TERENCE MARQUES | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $662,096 | ZRG1 |
| 2025 | Clinical Translation of a Choline-targeted NIR dye to guide lung cancer resection1R01CA293595-01A1 · under PAR-24-085 | DELIKATNY, EDWARD JSINGHAL, SUNIL | UNIVERSITY OF PENNSYLVANIA, PA | $657,168 | IPCA |
| 2025 | NT-I7, a novel long-acting interleukin-7, in combination with anti-PD-1 checkpoint blockade for the treatment of glioablastoma1R01CA288862-01A1 · under PAR-24-085 | CAMPIAN, JIAN | MAYO CLINIC ROCHESTER, MN | $639,004 | CONC |
| 2025 | Dual-tracer multiparametric imaging with a long-axial field-of-view PET to better characterize cancer1R37CA291948-01A1 · under PAR-24-085 | PANTEL, AUSTIN | UNIVERSITY OF PENNSYLVANIA, PA | $597,766 | CTIS |
| 2025 | Optimization of an active mutant KRAS peptide vaccine in colorectal cancer1R01CA296410-01 · under PAR-24-085 | AZAD, NILOFER S.ZAIDI, NEEHA | JOHNS HOPKINS UNIVERSITY, MD | $589,838 | CONC |
| 2025 | Phase 1/2 trial of PEP-CMV + nivolumab for newly diagnosed diffuse midline glioma/high-grade glioma and recurrent diffuse midline glioma/high-grade glioma, medulloblastoma, and ependymoma (PRiME II)1R01CA296813-01 · under PAR-24-085 | THOMPSON, ERIC | WASHINGTON UNIVERSITY, MO | $553,167 | CONC |
| 2025 | Targeting PD-L1 interactome signaling to enhance immunotherapy efficacy in head and neck squamous cell cancer2R01CA149456-11A1 · under PAR-24-085 | JIMENO, ANTONIO | UNIVERSITY OF COLORADO DENVER, CO | $528,427 | CONC |
| 2025 | A New Ultrasound Probe and Robot for Prostate Biopsy and Focal Therapy1R01CA303859-01 · under PAR-24-085 | STOIANOVICI, DAN | JOHNS HOPKINS UNIVERSITY, MD | $512,728 | IGIS |
| 2025 | Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.1R01CA296285-01A1 · under PAR-24-085 | CHANDARLAPATY, SARATYAEGER, RONA | SLOAN-KETTERING INST CAN RESEARCH, NY | $482,236 | CONC |
| 2025 | B7-H3 CAR T cells following initial radiation for children and young adults with diffuse intrinsic pontine glioma1R37CA289981-01A1 · under PAR-24-085 | VITANZA, NICHOLAS A | SEATTLE CHILDREN'S HOSPITAL, WA | $456,414 | CONC |
| 2025 | Therapeutic targeting of the tumor microenvironment in triple negative breast cancer patients at high risk of relapse and preclinical models of lung metastases1R01CA290013-01A1 · under PAR-24-085 | MITTAL, VIVEKVAHDAT, LINDA THERESA | DARTMOUTH-HITCHCOCK CLINIC, NH | $442,343 | CONC |
| 2025 | Improving immune modulation for smoldering myeloma1R01CA289978-01A1 · under PAR-24-085 | DHODAPKAR, MADHAV V | EMORY UNIVERSITY, GA | $32,666 | CONC |
| 2024 | The Effectiveness of Automated Multimodal Imaging in High Grade Squamous Intraepithelial Lesions (HSIL) Diagnosis for People Living with HIV: An International Trial2R01CA232890-06A1 · under PAR-21-033 | ANANDASABAPATHY, SHARMILACHIAO, ELIZABETH Y. | BAYLOR COLLEGE OF MEDICINE, TX | $988,950 | ZRG1 |
| 2024 | Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy1R37CA286450-01 · under PAR-21-033 | HAFFNER, MICHAEL CSCHWEIZER, MICHAEL T | FRED HUTCHINSON CANCER CENTER, WA | $720,165 | RTB |
| 2024 | Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate1R01CA286918-01A1 · under PAR-21-033 | BODEI, LISA | SLOAN-KETTERING INST CAN RESEARCH, NY | $704,422 | IPCA |
| 2024 | ESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate Cancer1R37CA282407-01A1 · under PAR-21-033 | MCCLURE, TIMOTHYNAGAR, HIMANSHU | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $698,716 | IGIS |
| 2024 | Interstitial Photodynamic Therapy Following Palliative Radiotherapy for Patients with Inoperable Malignant Central Airway Obstruction1R01CA283547-01A1 · under PAR-21-033 | BUSCH, THERESA MIVANICK, NATHANIEL TSHAFIRSTEIN, GAL | ROSWELL PARK CANCER INSTITUTE CORP, NY | $698,487 | RTB |
| 2024 | Novel PET Imaging to Guide Therapy in Hepatocellular Carcinoma1R01CA279467-01A1 · under PAR-21-033 | MANNING, HENRY CHARLES | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $678,515 | IGIS |
| 2024 | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor1R01CA279452-01A1 · under PAR-21-033 | MOGHADDAM, SEYED JAVAD MIRHASSANISKOULIDIS, FERDINANDOSTWEARDY, DAVID JOHN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $672,297 | CONC |
| 2024 | DCE-MRI guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer1R01CA290435-01 · under PAR-21-033 | EL-RAYES, BASSELKIM, HARRISONMASOOD, ASHIQ | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $669,747 | IGIS |
| 2024 | Neoadjuvant Immunotherapy Platform Study Reveals Mechanisms of Response in Hepatocellular Carcinoma (HCC)1R01CA285544-01A1 · under PAR-21-033 | HO, WON JINYARCHOAN, MARK | JOHNS HOPKINS UNIVERSITY, MD | $662,037 | CONC |
| 2024 | Mutant KRAS targeted vaccines for the interception of pancreatic cancer development1R37CA292056-01 · under PAR-21-033 | ZAIDI, NEEHA | JOHNS HOPKINS UNIVERSITY, MD | $659,090 | CONC |
| 2024 | Imaging tumor-associated macrophages in head and neck squamous cell carcinoma using fluorine-19 MRI1R01CA290014-01 · under PAR-21-033 | AHRENS, ERIC T.CALIFANO, JOSEPH A | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $655,700 | IPCA |
| 2024 | Causes and Consequences of Adenosine Signaling in Pancreatic Cancer1R01CA290888-01A1 · under PAR-21-033 | DONAHUE, TIMOTHY RRADU, CAIUS GABRIELWAINBERG, ZEV A | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $653,452 | CONC |
| 2024 | Bioactivity of CAR T cells secreting T cell engager-anitbodies in humans with glioblastoma1R01CA294071-01A1 · under PAR-21-033 | CHOI, BRYANMAUS, MARCELA VALDERRAMA | MASSACHUSETTS GENERAL HOSPITAL, MA | $652,725 | CNBT |
| 2024 | Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer1R01CA286443-01A1 · under PAR-21-033 | MAHAJAN, KIRANMAHAJAN, NUPAM P | WASHINGTON UNIVERSITY, MO | $652,414 | CONC |
| 2024 | Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung Cancer1R01CA282501-01A1 · under PAR-21-033 | LI, ZIHAI | OHIO STATE UNIVERSITY, OH | $641,336 | CONC |
| 2024 | Targeted EGFR for basal subtype pancreatic cancer1R01CA288145-01 · under PAR-21-033 | JOHNSON, GARY L.YEH, JEN JEN | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $639,879 | CONC |
| 2024 | Accelerated Brachytherapy Forward Chemoradiation Therapy (ABC-RT) for Cervical Cancer1R37CA287204-01A1 · under PAR-21-033 | CONTRERAS, JESSIKAMARKOVINA, STEPHANIE | WASHINGTON UNIVERSITY, MO | $634,894 | CONC |
| 2024 | Fecal microbial transplantation for chemotherapy behavioral side effects1R01CA287261-01 · under PAR-21-033 | PYTER, LEAH M | OHIO STATE UNIVERSITY, OH | $615,068 | CNBT |
| 2024 | Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma1R01CA294704-01 · under PAR-21-033 | LIN, YIPARK, SEAN SROBERTS, LEWIS R | MAYO CLINIC ROCHESTER, MN | $610,890 | ZRG1 |
| 2024 | ProAgio in Pancreatic Cancer1R01CA294647-01 · under PAR-21-033 | EL-RAYES, BASSELLIU, ZHI-REN | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $590,094 | ZRG1 |
| 2024 | Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancer1R01CA287866-01 · under PAR-21-033 | LESINSKI, GREGORY B.PAULOS, CHRYSTAL MARYWALLER, EDMUND K | EMORY UNIVERSITY, GA | $575,241 | CONC |
| 2024 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma1R01CA288692-01 · under PAR-21-033 | IYER, GOPASOLIT, DAVID B.YEH, RANDY | SLOAN-KETTERING INST CAN RESEARCH, NY | $556,681 | IGIS |
| 2024 | A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patients1R01CA292654-01 · under PAR-21-033 | BHOWMICK, NEIL A.POSADAS, EDWIN MELENCIO | CEDARS-SINAI MEDICAL CENTER, CA | $553,550 | CONC |
| 2024 | Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL1R01CA282408-01A1 · under PAR-21-033 | HESS, BRIANMEHROTRA, SHIKHAR | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $533,348 | CONC |
| 2024 | Addressing tumor heterogeneity in pediatric gliomas with precision adoptive T cell therapy1R01CA293376-01 · under PAR-21-033 | MITCHELL, DUANE A. | UNIVERSITY OF FLORIDA, FL | $474,656 | CNBT |
| 2024 | Targeting mitochondrial calcium to eradicate leukemia-initiating cells1R01CA292071-01 · under PAR-21-033 | JORDAN, CRAIG T.POLLYEA, DANIEL A | UNIVERSITY OF COLORADO DENVER, CO | $437,432 | ATA |
| 2024 | Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer1R01CA288880-01 · under PAR-21-033 | CERCEK, ANDREAYAEGER, RONA | SLOAN-KETTERING INST CAN RESEARCH, NY | $402,600 | CONC |
| 2024 | Evaluation of combination CLK/DYRK (Cirtuvivint) inhibition with PARP inhibition (Olaparib) in BRCA/HRD platinum resistant ovarian cancer1R01CA288651-01 · under PAR-21-033 | CORR, BRADLEY | UNIVERSITY OF COLORADO DENVER, CO | $400,444 | CONC |
| 2024 | TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer1R01CA288617-01 · under PAR-21-033 | BASAR, RAFETRAFEI, HINDREZVANI, KATY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $370,575 | CIC |
| 2024 | Secondary Molecular Imaging (SMI) for head and neck cancer1R01CA279249-01A1 · under PAR-21-033 | ROSENTHAL, EBEN L. | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $338,740 | IGIS |
| 2023 | EBNA1 Inhibitor for Treatment of EBV-positive DLBCL1R01CA282411-01 · under PAR-21-033 | LIEBERMAN, PAUL M.MESSICK, TROY EPORCU, PIERLUIGI | WISTAR INSTITUTE, PA | $745,842 | MCDC |
| 2023 | A randomized controlled phase 2 study of the ketogenic diet for patients with newly diagnosed glioblastoma in combination with standard-of-care treatment1R01CA276919-01 · under PAR-21-033 | FREEDLAND, STEPHEN JAYHU, JETHRO | CEDARS-SINAI MEDICAL CENTER, CA | $739,138 | CPSS |
| 2023 | Deciphering the Acidic Tumor Environment: A Phase I/IIa Study of Pre-Operative Multiparametric MRI and pHLIP® ICG Intra-Operative Fluorescence Imaging of Primary Breast Cancer1R01CA270018-01A1 · under PAR-21-033 | MORROW, MONICAPINKER-DOMENIG, KATJA | SLOAN-KETTERING INST CAN RESEARCH, NY | $706,536 | IGIS |
| 2023 | Intensive cholesterol-lowering intervention and anti-tumor immunity modeled in prostate cancer1R01CA280060-01A1 · under PAR-21-033 | KIM, HYUNG LTHOMPSON, PATRICIA ANN | CEDARS-SINAI MEDICAL CENTER, CA | $692,001 | CPSS |
| 2023 | Transfer of vaccine-induced immunity from immunocompetent stem cell donor as antiviral immunotherapy to protect high-risk transplant recipients from cytomegalovirus reactivation1R01CA266783-01A1 · under PAR-21-033 | DIAMOND, DON J | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $688,080 | CONC |
| 2023 | A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer1R01CA277161-01A1 · under PAR-21-033 | LUNDBERG, JENNIFER BAILEYTHOSANI, NIRAV | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $676,081 | CONC |
| 2023 | Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma1R01CA276684-01 · under PAR-21-033 | HEGDE, MEENAKSHI G | BAYLOR COLLEGE OF MEDICINE, TX | $667,761 | CONC |
| 2023 | A novel molecularly targeted theranostic approach via the alphavbeta6 integrin for the detection and treatment of metastatic cancers1R01CA279342-01 · under PAR-21-033 | FOSTER, CAMERON CARLSUTCLIFFE, JULIE L | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $664,690 | CTIS |
| 2023 | Combining immunotherapy with molecularly targeted radiation therapy1R01CA276785-01A1 · under PAR-21-033 | AGGARWAL, RAHULEVANS, MICHAEL JOHNFONG, LAWRENCE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $663,343 | CONC |
| 2023 | Sonobiopsy for Noninvasive Genetic Evaluation of Glioblastoma Patients1R01CA276174-01 · under PAR-21-033 | CHEN, HONGLEUTHARDT, ERIC CLAUDE | WASHINGTON UNIVERSITY, MO | $651,157 | CBSS |
| 2023 | Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer1R01CA281286-01 · under PAR-21-033 | CALIFANO, JOSEPH A | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $644,774 | ZRG1 |
| 2023 | Effects of Arginine Depletion Combined with Platinum-Taxane Chemotherapy in Aggressive Variant Prostate Cancers (AVPC)1R01CA283402-01 · under PAR-21-033 | APARICIO, ANAFRIGO, DANIEL EDWARDSHARMA, PADMANEE | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $636,578 | CONC |
| 2023 | A phase I/II study of combined therapy with Th17-inducing dendritic cells and pembrolizumab in patients with recurrent epithelial ovarian cancer1R01CA276313-01 · under PAR-21-033 | BLOCK, MATTHEW STEPHENKNUTSON, KEITH L. | MAYO CLINIC JACKSONVILLE, FL | $634,953 | CONC |
| 2023 | Exercise as an Immune Adjuvant for Gamma Delta T-cell Therapies in Hematologic Malignancies1R01CA277493-01 · under PAR-21-033 | KATSANIS, EMMANUELSIMPSON, RICHARD J | UNIVERSITY OF ARIZONA, AZ | $630,619 | CPSS |
| 2023 | Irreversible Electroporation (IRE) Combined with CD40 Agonism as In Situ Vaccine Therapy for Pancreatic Cancer1R01CA282439-01 · under PAR-21-033 | SCHOENBERGER, STEPHEN PHILIPWHITE, REBEKAH | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $629,181 | CONC |
| 2023 | Personalized vaccine immunotherapy in combination with anti-PD 1 antibody for recurrent or metastatic squamous cell carcinoma of the head and neck1R01CA262123-01A1 · under PAR-21-033 | SELVARAJ, PERIASAMYSHIN, DONG M | EMORY UNIVERSITY, GA | $625,507 | CONC |
| 2023 | Intravenous VSV virotherapy in lymphoma1R01CA262613-01A1 · under PAR-21-033 | BENNANI, NABILA NORAPENG, KAH-WHYE | MAYO CLINIC ROCHESTER, MN | $619,753 | DT |
| 2023 | Quantitative molecular MR-PET imaging of glycolysis in glioblastoma1R01CA279984-01 · under PAR-21-033 | ELLINGSON, BENJAMIN M.NATHANSON, DAVID A. | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $619,045 | MCDC |
| 2023 | AI-Assisted Microendoscopy for the Early Detection of Esophageal Cancer2R01CA181275-07 · under PAR-21-033 | ANANDASABAPATHY, SHARMILA | BAYLOR COLLEGE OF MEDICINE, TX | $612,665 | IGIS |
| 2023 | Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies1R01CA276374-01A1 · under PAR-21-033 | ALINARI, LAPODE LIMA, MARCOSVASU, SUMITHIRA | OHIO STATE UNIVERSITY, OH | $609,273 | CONC |
| 2023 | Development of contrast agents to facilitate image-guided surgery1R01CA281098-01A1 · under PAR-21-033 | JAIN, AJAYMCNALLY, LACEY R | UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR, OK | $607,029 | IPCA |
| 2023 | A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation1R01CA272639-01A1 · under PAR-21-033 | HEIMBERGER, AMY BETHKUMTHEKAR, PRIYA U. | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $601,792 | CONC |
| 2023 | Novel synthetic lethality strategy for TP53 mutant colorectal cancer1R37CA282430-01 · under PAR-21-033 | FOUNTZILAS, CHRISTOS | ROSWELL PARK CANCER INSTITUTE CORP, NY | $585,984 | MCTA |
| 2023 | Immune Therapy for Brain Metastasis1R01CA269286-01A1 · under PAR-21-033 | JILAVEANU, LUCIA BEATRICEKLUGER, HARRIET M. | YALE UNIVERSITY, CT | $583,091 | CONC |
| 2023 | Glioma intelligence from behind enemy lines1R37CA276851-01 · under PAR-21-033 | BURNS, TERRY | MAYO CLINIC ROCHESTER, MN | $545,993 | DT |
| 2023 | Targeting Tryptophan Metabolism in Rectal Cancer1R01CA278197-01A1 · under PAR-21-033 | CIORBA, MATTHEW AARONPARK, HAESEONG | WASHINGTON UNIVERSITY, MO | $513,828 | MCDC |
| 2023 | Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer1R01CA273246-01A1 · under PAR-21-033 | ARTEAGA, CARLOS LKENNEDY, LAURA CARPIN | VANDERBILT UNIVERSITY MEDICAL CENTER, TN | $510,310 | CONC |
| 2023 | Toward Clinical Trial: AXL-STAT3 Targeting of Lung Tumor Microenvironments1R01CA269766-01A1 · under PAR-21-033 | TAVERNA, JOSEPHINE A | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $478,705 | CONC |
| 2023 | Targeting PLK1 in RAS mutant chronic myelomonocytic leukemia1R01CA272496-01A1 · under PAR-21-033 | PATNAIK, MRINAL SHIV | MAYO CLINIC ROCHESTER, MN | $427,131 | CONC |
| 2023 | Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.1R01CA280827-01 · under PAR-21-033 | BASAR, RAFETDAHER, MAYREZVANI, KATY | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $370,575 | CIC |
| 2023 | Defining Optimal Radiotherapy Dose and Fractionation in Combination with Preoperative Immuno-Chemotherapy in Early-Stage Triple Negative Breast Cancer1R01CA274254-01 · under PAR-21-033 | DUDA, DAN GABRIELGUPTA, GAORAV P.HO, ALICE | DUKE UNIVERSITY, NC | $1 | RTB |
| 2022 | Enhancing B7-H3-CAR T cell therapy for pediatric solid tumors1R01CA262589-01A1 · under PAR-21-033 | DERENZO, CHRISTOPHER C.GOTTSCHALK, STEPHEN | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN | $734,126 | CONC |
| 2022 | Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma1R01CA265009-01A1 · under PAR-21-033 | THOMAS, PAUL G.YARCHOAN, MARK | JOHNS HOPKINS UNIVERSITY, MD | $733,308 | ZRG1 |
| 2022 | Engineered anti-PSCA antibodies for immunoPET and targeted therapy of pancreatic cancer1R01CA266665-01 · under PAR-21-033 | WU, ANNA M | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $729,981 | IPCA |
| 2022 | A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer1R01CA266874-01A1 · under PAR-21-033 | PRICEMAN, SAULRODRIGUEZ-RODRIGUEZ, LORNA | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $723,036 | CONC |
| 2022 | Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T cells for Treatment of Primary Central Nervous System Lymphoma1R01CA266611-01A1 · under PAR-21-033 | FORMAN, STEPHEN JSIDDIQI, TANYAWANG, XIULI | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $719,558 | CONC |
| 2022 | Implementation of an interventional, risk-adapted clinical trial for children with newly diagnosed juvenile myelomonocytic leukemia.1R37CA266550-01A1 · under PAR-21-033 | STIEGLITZ, ELLIOT | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $711,288 | CONC |
| 2022 | Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB1221R01CA266757-01 · under PAR-21-033 | HAFLER, DAVID A.OMURO, ANTONIO M | YALE UNIVERSITY, CT | $695,125 | CONC |
| 2022 | Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer1R01CA267690-01A1 · under PAR-21-033 | SEGAL, BRAHM H.ZSIROS, EMESE | ROSWELL PARK CANCER INSTITUTE CORP, NY | $693,903 | CONC |
| 2022 | BAFF-R CAR T cell therapy for ALL1R01CA269569-01 · under PAR-21-033 | ALDOSS, IBRAHIMKWAK, LARRY WWANG, XIULI | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $677,623 | CONC |
| 2022 | Coffee and metabolites modulating the gut microbiome for improved colorectal cancer survival1R01CA263776-01A1 · under PAR-21-033 | SONG, MINGYANG | HARVARD SCHOOL OF PUBLIC HEALTH, MA | $676,076 | CPSS |
| 2022 | Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer1R01CA260902-01A1 · under PAR-21-033 | POWELL, DANIEL J. | UNIVERSITY OF PENNSYLVANIA, PA | $672,991 | ZRG1 |
| 2022 | Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor1R01CA269516-01 · under PAR-21-033 | JOHNSON, FAYESIKORA, ANDREWTWEARDY, DAVID JOHN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $671,730 | DT |
| 2022 | Development of CD46 theranostics for imaging and treatment of multiple myeloma1R01CA271606-01A1 · under PAR-21-033 | FLAVELL, ROBERT RICHARDWIITA, ARUN P. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $670,212 | IPCA |
| 2022 | Immunotherapy of Uveal Melanoma using PRAME Vaccine in Combination with Adoptive T Cell Therapy1R01CA266714-01A1 · under PAR-21-033 | PATEL, SAPNAYEE, CASSIAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $668,196 | CII |
| 2022 | Understanding Treatment Response Patterns And Therapy Resistance In IDH-Mutant AML1R01CA262496-01A1 · under PAR-21-033 | EISFELD, ANN-KATHRINMARDIS, ELAINE RMIMS, ALICE SCOTT | OHIO STATE UNIVERSITY, OH | $664,967 | CONC |
| 2022 | Phase 0/1 trial of ONC206 - a novel imipridone for children with diffuse midline gliomas and recurrent malignant brain tumors1R01CA266596-01A1 · under PAR-21-033 | MUELLER, SABINE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $664,049 | CONC |
| 2022 | Receptor-Targeted Fluorescence-Guided Surgery in Pancreatic Neuroendocrine Tumors1R01CA263512-01A1 · under PAR-21-033 | AZHDARINIA, ALIIKOMA, NARUHIKO | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $662,090 | IPCA |
| 2022 | Integrating Epigenetic Modulation into DNA Damage Repair1R01CA255613-01A1 · under PAR-21-033 | MUNSTER, PAMELA N. | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $656,890 | CONC |
| 2022 | PSMA-PET to Guide Prostatectomy: Can PSMA-PET Appropriately Modify Surgery, Reduce Nerve Damage and Optimize Quality-of-Life?1R01CA258994-01A1 · under PAR-21-033 | BAHLER, CLINTON DAVID | INDIANA UNIVERSITY INDIANAPOLIS, IN | $637,698 | IGIS |
| 2022 | IL-15 and -21 armored GPC3-specific CAR T cells for children with solid tumors1R01CA258866-01A1 · under PAR-21-033 | HECZEY, ANDRAS A. | BAYLOR COLLEGE OF MEDICINE, TX | $635,004 | CONC |
| 2022 | Combating melanoma resistance by targeting ABL1/21R01CA258751-01A1 · under PAR-21-033 | KOLESAR, JILL MARIEPLATTNER, RINAWILSON, MELISSA A | UNIVERSITY OF KENTUCKY, KY | $634,772 | CONC |
| 2022 | Radiation and dendritic cells to hepatomas to improve immunotherapy response1R01CA274985-01 · under PAR-21-033 | LIN, YIPARK, SEAN SROBERTS, LEWIS R | MAYO CLINIC ROCHESTER, MN | $632,389 | RTB |
| 2022 | Targeting polo-like kinase for therapy of small cell lung cancer1R01CA273216-01 · under PAR-21-033 | OWONIKOKO, TAOFEEK K | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $630,466 | CONC |
| 2022 | Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors1R01CA266457-01A1 · under PAR-21-033 | VILLALONA, MIGUEL AYU, JIANHUA | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $620,673 | CONC |
| 2022 | Use of radioprotector in rectal cancer1R01CA255618-01A1 · under PAR-21-033 | LIN, CHIOBERLEY-DEEGAN, REBECCA E | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $615,378 | CONC |
| 2022 | Precision Imaging of Breast Cancer for Guiding Neoadjuvant Endocrine Therapy1R01CA272571-01 · under PAR-21-033 | FOWLER, AMY | UNIVERSITY OF WISCONSIN-MADISON, WI | $605,718 | CTIS |
| 2022 | Targeting c-Myc stability in c-Myc overexpressing large B-cell lymphoma1R01CA266682-01 · under PAR-21-033 | ALINARI, LAPO | OHIO STATE UNIVERSITY, OH | $601,346 | CONC |
| 2022 | Overcoming metastatic spread of osteosarcoma with RNA loaded nanoparticles1R01CA266857-01A1 · under PAR-21-033 | SAYOUR, ELIAS | UNIVERSITY OF FLORIDA, FL | $560,034 | CONC |
| 2022 | Targeting MicroRNAs to Eradicate Leukemia Stem Cells2R01CA205247-06 · under PAR-21-033 | KUO, YA-HUEIMARCUCCI, GUIDONGUYEN, LE XUAN TRUONG | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $505,757 | DT |
| 2022 | Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC1R01CA262292-01A1 · under PAR-21-033 | SALGIA, RAVIWHEELER, DERIC L | UNIVERSITY OF WISCONSIN-MADISON, WI | $504,584 | DT |
| 2022 | Contrast Enhanced Mammography (CEM) to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study1R01CA258898-01A1 · under PAR-21-033 | ZULEY, MARGARITA L | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $471,449 | CTIS |
| 2022 | Connectivity mapping identified novel combination therapy for glioblastoma1R01CA273319-01 · under PAR-21-033 | BATRA, SURINDER K.SHONKA, NICOLE | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $445,918 | DT |
| 2022 | Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia1R01CA266298-01A1 · under PAR-21-033 | DAVIDS, MATTHEW S | DANA-FARBER CANCER INST, MA | $421,375 | CONC |
| 2022 | Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers1R01CA272982-01 · under PAR-21-033 | SHAPIRO, GEOFFREY I | DANA-FARBER CANCER INST, MA | $414,529 | DT |
| 2022 | A Multifaceted Radiomics Model to Predict Cervical Lymph Node Metastasis for Involved Nodal Radiation Therapy1R01CA251792-01A1 · under PAR-21-033 | SHER, DAVIDWANG, JING | UT SOUTHWESTERN MEDICAL CENTER, TX | $410,620 | RTB |
| 2022 | Clinical evaluation and non-invasive monitoring of Vorasidenib in combination with tumor specific peptide PEP-IDH1M vaccine therapy in patients with recurrent mutant IDH1 glioma1R01CA271129-01 · under PAR-21-033 | PETERS, KATHERINE BSOHER, BRIAN J | DUKE UNIVERSITY, NC | $392,725 | CNBT |
| 2022 | Optimizing radiation therapy through the manipulation of glutamine metabolism2R01CA181745-06A1 · under PAR-21-033 | SCHWARZ, JULIE KRISTINA | WASHINGTON UNIVERSITY, MO | $374,063 | RTB |
| 2022 | Inhibition of T-cell Receptor Signaling for Treatment of Adult T-cell Leukemia Lymphoma1R01CA258359-01A1 · under PAR-21-033 | RATNER, LEERAUCH, DANIEL ARTHUR | WASHINGTON UNIVERSITY, MO | $360,282 | CONC |
| 2021 | Validation of epigenomic biomarkers for thyroid cancer diagnostics1R01CA241845-01A1 · under PAR-18-560 | HAHN, MARIAYIM, JOHN H | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $958,109 | CBSS |
| 2021 | Tumor Subtypes and Therapy Response in Pancreatic Cancer2R01CA199064-06A1 · under PAR-18-560 | TSAI, SUSANYEH, JEN JEN | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $806,124 | CONC |
| 2021 | Personalized Adoptive T-cell Therapy for AML1R01CA262629-01 · under PAR-18-560 | AVIGAN, DAVID E.ROSENBLATT, JACALYN | BETH ISRAEL DEACONESS MEDICAL CENTER, MA | $762,763 | CONC |
| 2021 | Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal2R01CA143130-11A1 · under PAR-18-560 | NAKAGAWA, MAYUMI | UNIV OF ARKANSAS FOR MED SCIS, AR | $727,272 | CONC |
| 2021 | A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients1R01CA260872-01 · under PAR-18-560 | AMIN, HESHAM MDUDA, DAN GABRIELKASEB, AHMED | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $711,171 | CONC |
| 2021 | CAR T Cells for Advanced Thyroid Cancer1R01CA254035-01A1 · under PAR-18-560 | FAHEY, THOMAS JJIN, MOONSOO M.VAN BESIEN, KOEN WALTER | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $693,091 | CONC |
| 2021 | Targeting obesity to improve survival from childhood acute lymphoblastic leukemia1R37CA252236-01A1 · under PAR-18-560 | ORGEL, ETAN | CHILDREN'S HOSPITAL OF LOS ANGELES, CA | $687,010 | CONC |
| 2021 | Developing Safe and Effective GD2-CAR T Cell Therapy for Diffuse Midline Gliomas1R01CA263500-01 · under PAR-18-560 | MACKALL, CRYSTALMONJE-DEISSEROTH, MICHELLE | STANFORD UNIVERSITY, CA | $671,445 | CONC |
| 2021 | Measuring Metabolic Activity in Prostate Cancer Bone Metastases Using Hyperpolarized 13C Pyruvate MRI for Improved Targeted Therapy Monitoring1R01CA256740-01 · under PAR-18-560 | AGGARWAL, RAHULVIGNERON, DANIEL B | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $669,448 | IGIS |
| 2021 | Overcoming Hypoxic Resistance in Non-Small Cell Lung Cancer By Targeting Mitochondrial Metabolism1R01CA262388-01 · under PAR-18-560 | DENKO, NICHOLAS C.LI, ZIHAIWILLIAMS, TERENCE MARQUES | OHIO STATE UNIVERSITY, OH | $650,406 | ZRG1 |
| 2021 | Pacritinib in rel/refr T-cell lymphomas1R01CA265929-01 · under PAR-18-560 | WILCOX, RYAN A | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $645,497 | CONC |
| 2021 | Multi-receptor Targeting of Glioblastoma1R01CA256285-01A1 · under PAR-18-560 | DEBINSKI, WALDEMAR | WAKE FOREST UNIVERSITY HEALTH SCIENCES, NC | $642,795 | CONC |
| 2021 | Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer1R01CA248147-01A1 · under PAR-18-560 | YOON, HARRY H | MAYO CLINIC ROCHESTER, MN | $640,182 | CONC |
| 2021 | Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer1R01CA260678-01 · under PAR-18-560 | DONAHUE, TIMOTHY RRADU, CAIUS GABRIELWAINBERG, ZEV A | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $634,454 | DT |
| 2021 | Targeting B7-H3 in ovarian cancer1R01CA256898-01 · under PAR-18-560 | DOTTI, GIANPIETROGEHRIG, PAOLA ALVAREZ | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $632,310 | ZRG1 |
| 2021 | A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients1R01CA255639-01A1 · under PAR-18-560 | PAIK, PAUL KRIESS, JONATHAN W | SLOAN-KETTERING INST CAN RESEARCH, NY | $628,641 | CONC |
| 2021 | Understanding and targeting MAPK pathway activation in NF1-deficient malignant peripheral nerve sheath tumor (MPNST)1U01CA252048-01A1 · under PAR-18-560 | CHI, PING | SLOAN-KETTERING INST CAN RESEARCH, NY | $622,197 | DT |
| 2021 | Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response1R01CA255650-01A1 · under PAR-18-560 | CURTI, BRENDAN DREDMOND, WILLIAM L | PROVIDENCE PORTLAND MEDICAL CENTER, OR | $593,078 | CONC |
| 2021 | Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients1R01CA255960-01 · under PAR-18-560 | KEYOMARSI, KHANDAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $587,495 | CONC |
| 2021 | Training Swallowing Initiation during Expiration: Impact on Safety and Efficiency Following Treatment for Oropharyngeal Head and Neck Cancer1R01CA262502-01 · under PAR-18-560 | MARTIN-HARRIS, BONNIE J | NORTHWESTERN UNIVERSITY, IL | $586,422 | MFSR |
| 2021 | Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial2R01CA197296-06 · under PAR-18-560 | JAFFEE, ELIZABETH M.ZHENG, LEI | JOHNS HOPKINS UNIVERSITY, MD | $581,039 | CONC |
| 2021 | Targeting immunosuppressive adenosine in patients with metastatic non-small cell lung cancer1R01CA248741-01A1 · under PAR-18-560 | CARBONE, DAVID P.DIKOV, MIKHAIL M | OHIO STATE UNIVERSITY, OH | $577,069 | CONC |
| 2021 | Reduction of Tumor-Positive Margins in Oncology Surgery1R37CA245157-01A1 · under PAR-18-560 | WARRAM, JASON MORGAN | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $563,251 | CONC |
| 2021 | Targeting Nucleotide Metabolism to Overcome Therapy Resistance in Glioblastoma1R37CA258346-01 · under PAR-18-560 | WAHL, DANIEL R | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $554,870 | RTB |
| 2021 | Re-wiring PDAC Tumor Immunity Through Dendritic Cells1R01CA262506-01 · under PAR-18-560 | DENARDO, DAVID GDESELM, CARL | WASHINGTON UNIVERSITY, MO | $551,987 | CII |
| 2021 | Neoadjuvant Immunotherapy with Intratumoral CPG and PD-1 Blockade in Melanoma1R01CA257265-01 · under PAR-18-560 | DAVAR, DIWAKARZAROUR, HASSANE M | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $551,927 | CONC |
| 2021 | Molecular Pathogenesis and Therapy of Systemic Histiocytic Neoplasms1R37CA259260-01 · under PAR-18-560 | DIAMOND, ELI LOUS | SLOAN-KETTERING INST CAN RESEARCH, NY | $551,042 | CONC |
| 2021 | Targeted Therapies for Lymphoid Malignancies2R01CA177292-06A1 · under PAR-18-560 | ROGERS, KERRY ANNEWOYACH, JENNIFER A. | OHIO STATE UNIVERSITY, OH | $538,241 | CONC |
| 2021 | Novel combination therapy for AML expressing mutant RUNX11R01CA262636-01 · under PAR-18-560 | BHALLA, KAPILDINARDO, COURTNEYTAKAHASHI, KOICHI | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $534,187 | CONC |
| 2021 | Precision targeting of T cell cytotoxicity with PET1R01CA258297-01 · under PAR-18-560 | AGGARWAL, RAHULCRAIK, CHARLES SCOTTEVANS, MICHAEL JOHNFONG, LAWRENCE | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $524,205 | CTIS |
| 2021 | Repolarizing the Tumor and Metastatic Microenvironments to Treat Patients with Pancreatic Cancer1R01CA262580-01 · under PAR-18-560 | GERBER, SCOTT ANDREWLINEHAN, DAVID C | UNIVERSITY OF ROCHESTER, NY | $516,038 | CONC |
| 2021 | Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia1R01CA265095-01 · under PAR-18-560 | BUDDE, LIHUA ELIZABETHCALIGIURI, MICHAEL AYU, JIANHUA | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $489,159 | CONC |
| 2021 | Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas1R37CA251978-01A1 · under PAR-18-560 | SAYOUR, ELIAS | UNIVERSITY OF FLORIDA, FL | $472,806 | CII |
| 2021 | Improving efficacy of radioiodine treatment of thyroid cancer1R01CA249663-01A1 · under PAR-18-560 | FAGIN, JAMES AHO, ALAN L. | SLOAN-KETTERING INST CAN RESEARCH, NY | $471,416 | MCE |
| 2021 | Increasing nerve-sparing radical prostatectomy rates using intraoperative nonlinear microscopy1R01CA249151-01A1 · under PAR-18-560 | FUJIMOTO, JAMES G | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $466,284 | IGIS |
| 2021 | Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment1R01CA249811-01A1 · under PAR-18-560 | MARANCHIE, JODI KATHLEENSTORKUS, WALTER J. | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $456,744 | CII |
| 2021 | Interactions of Androgen Production, Uptake and Metabolism on outcome in Castration Resistant Prostate Cancer1R01CA249279-01A1 · under PAR-18-560 | HALABI, SUSANRYAN, CHARLES JAMESSHARIFI, NIMA | UNIVERSITY OF MINNESOTA, MN | $426,729 | CONC |
| 2021 | Targeting epigenetic regulation via Bromodomain and Extraterminal (BET) domain inhibition for treatment of GVHD1R01CA252469-01A1 · under PAR-18-560 | CHOE, HANNAHRANGANATHAN, PARVATHI | OHIO STATE UNIVERSITY, OH | $415,000 | CONC |
| 2021 | A First-in-Human Phase I Clinical Trial of Mitochondrial-Targeted Hsp90 Inhibitor, Gamitrinib1R01CA225913-01A1 · under PAR-18-560 | ALTIERI, DARIO COLSZANSKI, ANTHONY J. | WISTAR INSTITUTE, PA | $410,285 | CONC |
| 2021 | Robot-Assisted Personalized Prostate Biopsy1R01CA247959-01A1 · under PAR-18-560 | STOIANOVICI, DAN | JOHNS HOPKINS UNIVERSITY, MD | $316,306 | BTSS |
| 2021 | Two photon fluorescence microscopy for dermatologic surgery and biopsy1R37CA258376-01 · under PAR-18-560 | GIACOMELLI, MICHAEL GENE | UNIVERSITY OF ROCHESTER, NY | $308,061 | IGIS |
| 2020 | Clinical Evaluation of Chlorotoxin-redirected Chimeric Antigen Receptor (CAR) T cells for Treatment of Glioblastoma1R01CA254271-01 · under PAR-18-560 | BADIE, BEHNAMBROWN, CHRISTINE | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $768,221 | CONC |
| 2020 | Evaluation of an implantable microdevice for rapid cancer drug screening directly in T cell lymphoma patients1R37CA252312-01 · under PAR-18-560 | LAROCCA, CECILIA | BRIGHAM AND WOMEN'S HOSPITAL, MA | $759,496 | CONC |
| 2020 | Evaluation of Transperineal Biopsy under Local Anesthesia, a Novel approach to Decrease Post-Biopsy Infections and Improve Cancer Detection1R01CA241758-01A1 · under PAR-18-560 | ALLAF, MOHAMADHU, JIMSCHAEFFER, EDWARD MATTHEW | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $737,794 | NRCS |
| 2020 | A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers1R01CA238392-01A1 · under PAR-18-560 | LEE, NANCY Y | SLOAN-KETTERING INST CAN RESEARCH, NY | $716,756 | RTB |
| 2020 | Conformal Total Body and Marrow Irradiation for Leukemia2R01CA154491-07A1 · under PAR-18-560 | HUI, SUSANTA KWONG, JEFFREY Y | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $708,512 | RTB |
| 2020 | Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucel1R01CA252940-01 · under PAR-18-560 | MAUS, MARCELA VALDERRAMA | MASSACHUSETTS GENERAL HOSPITAL, MA | $697,200 | CONC |
| 2020 | Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)1U01CA238444-01A1 · under PAR-18-560 | CERCEK, ANDREAIACOBUZIO-DONAHUE, CHRISTINE AJARNAGIN, WILLIAM ROBERT | SLOAN-KETTERING INST CAN RESEARCH, NY | $682,721 | CONC |
| 2020 | Tailoring CAR T cell therapy for Hodgkin Lymphoma1R01CA247497-01A1 · under PAR-18-560 | SAVOLDO, BARBARA | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $634,693 | CONC |
| 2020 | Pneumatic Drill and Robot for MRI-Guided Pediatrics Long Bone Biopsy1R01CA248191-01 · under PAR-18-560 | CLEARY, KEVIN R.SHARMA, KARUN V | CHILDREN'S RESEARCH INSTITUTE, DC | $631,110 | IGIS |
| 2020 | Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer1R01CA247471-01 · under PAR-18-560 | BATRA, SURINDER K.JAIN, MANEESHSALGIA, RAVI | UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE | $614,511 | CONC |
| 2020 | Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition1R01CA244936-01A1 · under PAR-18-560 | WEBER, JEFFREY S | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $610,766 | CBSS |
| 2020 | Fluorescence-guided resection of breast tumors using a topically-applied molecular probe1R01CA246678-01 · under PAR-18-560 | BASILION, JAMES PETER | CASE WESTERN RESERVE UNIVERSITY, OH | $595,998 | IPCA |
| 2020 | Quantitative PET Imaging of Hepatocellular Carcinoma (HCC)1R01CA239694-01A1 · under PAR-18-560 | MANNING, HENRY CHARLES | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $585,790 | CTIS |
| 2020 | Novel Methods of Chemo-sensitizing Low-proliferative Disseminated Tumor Cells in Triple Negative Breast Cancer1R01CA238387-01A1 · under PAR-18-560 | TRAN, DAVID D | UNIVERSITY OF FLORIDA, FL | $521,764 | CONC |
| 2020 | Understanding Richter's Transformation in the targeted therapies era1R01CA240493-01A1 · under PAR-18-560 | LAPALOMBELLA, ROSA | OHIO STATE UNIVERSITY, OH | $474,404 | CONC |
| 2020 | Phase I/II clinical trial of HDAC inhibition for GVHD prevention in children, adolescents, and young adults1R01CA249211-01 · under PAR-18-560 | CHOI, SUNG WON | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $466,089 | CONC |
| 2020 | Microbubble Cavitation for Improving Hepatocellular Carcinoma Radioembolization1R01CA238241-01A1 · under PAR-18-560 | EISENBREY, JOHNSHAW, COLETTE | THOMAS JEFFERSON UNIVERSITY, PA | $454,127 | RTB |
| 2020 | Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity1R01CA248917-01 · under PAR-18-560 | DENARDO, DAVID GKIM, HYUNSCHWARZ, JULIE KRISTINA | WASHINGTON UNIVERSITY, MO | $453,504 | RTB |
| 2020 | [18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors1R01CA240638-01A1 · under PAR-18-560 | KUMMAR, SHIVAANIMARI APARICI, CARINA | STANFORD UNIVERSITY, CA | $423,444 | CTIS |
| 2020 | Blood-brain barrier disruption with implantable ultrasound to enhance paclitaxel delivery: A Phase 1-2 clinical trial in recurrent glioblastoma1R01CA245969-01A1 · under PAR-18-560 | SONABEND, ADAM MSTUPP, ROGER | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $419,323 | CONC |
| 2020 | Molecular Phenotyping and Image-Guidance for Surgical Treatment of High-Risk Prostate Cancer Using Ultrasmall Silica Nanoparticles1R01CA243085-01A1 · under PAR-18-560 | BRADBURY, MICHELLE STOUIJER, ABDELKRIM K.WIESNER, ULRICH | SLOAN-KETTERING INST CAN RESEARCH, NY | $396,582 | IGIS |
| 2020 | Small Molecule PSMA-Targeted Alpha Therapy2R01CA184228-06 · under PAR-18-560 | POMPER, MARTIN GZALUTSKY, MICHAEL ROD | JOHNS HOPKINS UNIVERSITY, MD | $319,250 | IPCA |
| 2020 | Developing BRAF mutant and BRAF wild-type selective strategies for radiosensitization in Anaplastic Thyroid Cancer1R01CA246553-01A1 · under PAR-18-560 | SHAH, MANISHA HWILLIAMS, TERENCE MARQUES | OHIO STATE UNIVERSITY, OH | $193,780 | MCE |
| 2020 | CD38-targeted immunoPET of myeloma: Phase 2 trial of clinical applications1R01CA248398-01 · under PAR-18-560 | LANDGREN, CARL OLAULANER, GARY ALLAN | SLOAN-KETTERING INST CAN RESEARCH, NY | $135,622 | IGIS |
| 2019 | A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma1R01CA235667-01A1 · under PAR-18-560 | ADUSUMILLI, PRASAD S.ZAUDERER, MARJORIE G. | SLOAN-KETTERING INST CAN RESEARCH, NY | $727,344 | CONC |
| 2019 | Targeting Alterations of the NOTCH1 Pathway in Head & Neck Squamous Cell Carcinoma (HNSCC)1R01CA235620-01A1 · under PAR-18-560 | FREDERICK, MITCHELL J.JANKU, FILIPJOHNSON, FAYE | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $666,259 | CONC |
| 2019 | Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma1R01CA236500-01 · under PAR-18-560 | BADIE, BEHNAMBROWN, CHRISTINE | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $665,839 | CII |
| 2019 | Clinical Development of Rhenium Nanoliposomes (RNL186) for Glioblastoma1R01CA235800-01A1 · under PAR-18-560 | BRENNER, ANDREW JACOB | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, TX | $660,911 | CONC |
| 2019 | Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)1R01CA235681-01A1 · under PAR-18-560 | HAHN, NOAH M | JOHNS HOPKINS UNIVERSITY, MD | $656,816 | CONC |
| 2019 | Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma1R01CA239462-01A1 · under PAR-18-560 | CHAUMEIL, MYRIAM MARIANNERUBENSTEIN, JAMES LOUIS | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | $650,020 | CONC |
| 2019 | Multi-site adaptive trial of a technology-based, EHR-integrated physical activity intervention in breast and endometrial cancer survivors1R37CA225877-01A1 · under PAR-18-560 | CADMUSBERTRAM, LISA ANNEPHILLIPS, SIOBHAN MARIE | UNIVERSITY OF WISCONSIN-MADISON, WI | $646,190 | ZCA1 |
| 2019 | Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies1R01CA235633-01 · under PAR-18-560 | COLEVAS, A. DIMITRIOS | STANFORD UNIVERSITY, CA | $629,493 | CONC |
| 2019 | Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes1R01CA226992-01A1 · under PAR-18-560 | JANI, ASHESHSCHUSTER, DAVID MICHAEL | EMORY UNIVERSITY, GA | $629,419 | RTB |
| 2019 | Targeting Neoantigens in Triple Negative Breast Cancer1R01CA240983-01 · under PAR-18-560 | GILLANDERS, WILLIAM E.SCHREIBER, ROBERT DAVID | WASHINGTON UNIVERSITY, MO | $629,038 | CONC |
| 2019 | Optical Imaging to Improve Surgery & Targeted Therapy in Brain Tumors1R01CA239257-01A1 · under PAR-18-560 | LI, GORDONROSENTHAL, EBEN L. | STANFORD UNIVERSITY, CA | $626,189 | IGIS |
| 2019 | Adoptive T Cell Therapy for Pancreatic Cancer1R01CA237672-01 · under PAR-18-560 | YEE, CASSIAN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $623,803 | CII |
Showing the 200 most recent of 216 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.